News Sentiment

IKT sentiment intelligence

Inhibikase Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 41 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.11 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 32

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+3.4% over one week, +15.3% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 3.4% Price confirming higher
Trend fit Trend active 15.3% over four weeks
Fair value 14.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 27
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 32
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 6
MarketBeat 5
TradingView 4
simplywall.st 3
GlobeNewswire 3
Moomoo 2
MLQ.ai 1

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 12
Analyst action 4
Deals and strategy 3
Balance sheet 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 41
Moomoo Direct company coverage

Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

This article is a preliminary proxy statement (PRE 14A) filed by Inhibikase Therapeutics. The document pertains to a merger or acquisition, indicating that the company is involved in a corporate transaction that requires shareholder approval or notification. The specific details

Tone
Neutral 50/100
Event
Deals and strategy
Published
21 Jul 2026 08:41
Source
Moomoo
MLQ.ai Direct company coverage

Frontier tech research, news & data

This article provides an inventory turnover analysis for Inhibikase Therapeutics, Inc. (IKT), drawing data from SEC EDGAR filings. It presents both annual and quarterly inventory turnover figures, noting that the company's inventory turnover was "—" for all listed periods, indica

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 08:41
Source
MLQ.ai
Bitget Direct company coverage

RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics

RA Capital Management has filed an initial beneficial ownership statement (Form 3) for Inhibikase Therapeutics, declaring indirect ownership of 25 million common shares. This filing indicates RA Capital owns 10% of Inhibikase Therapeutics. The event date for the ownership was Jul

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2026 20:11
Source
Bitget
MarketBeat Direct company coverage

Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen has downgraded Inhibikase Therapeutics (NASDAQ:IKT) from a "sell" to a "strong sell" rating. Despite this downgrade, other analysts maintain a more positive outlook, with a consensus "Buy" rating and an average price target of $5.40. The company, a clinical-stage

Tone
Negative 34/100
Event
Analyst action
Published
18 Jul 2026 05:39
Source
MarketBeat
Stock Titan Direct company coverage

RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase

RA Capital, through its Healthcare Fund, has reported a 15.9% stake in Inhibikase Therapeutics (IKT), holding 25 million shares. This ownership arose from an at-the-market offering on July 10, 2026, and the percentage is calculated based on an updated share count including these

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jul 2026 21:39
Source
Stock Titan
Moomoo Direct company coverage

Inhibikase Therapeutics Shares Rise on $50M At‐the‐Market Share Sale

Inhibikase Therapeutics recently announced a $50 million "At-the-Market" (ATM) share sale agreement with A.G.P./Alliance Global Partners. This agreement allows the company to sell common stock periodically, aiming to raise capital for general corporate purposes, including R&D and

Tone
Positive 71/100
Event
Market update
Published
15 Jul 2026 07:10
Source
Moomoo
MarketBeat Direct company coverage

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Brokerages

Nine brokerages have given Inhibikase Therapeutics (NASDAQ:IKT) an average "Buy" rating, with a consensus 12-month price target of $5.40. The ratings include one "sell," one "hold," three "buy," and four "strong buy" recommendations. Recent analyst activity includes upgrades, new

Tone
Positive 67/100
Event
Analyst action
Published
15 Jul 2026 06:12
Source
MarketBeat
Investing.com Direct company coverage

Inhibikase raises $50 million through stock sale to RA Capital

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has raised $50 million by selling 25 million shares of common stock to RA Capital Management. This financing significantly increases the company's capital, validating its clinical-stage pipeline. The funds, combined with existing cash, a

Tone
Positive 73/100
Event
Balance sheet
Published
14 Jul 2026 14:18
Source
Investing.com
Investing.com Canada Direct company coverage

Inhibikase raises $50 million through stock sale to RA Capital By Investing.com

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has successfully raised $50 million by selling 25 million shares of common stock to RA Capital Management. This financing significantly boosts the clinical-stage company's financial position, supporting its operations through a key data

Tone
Positive 74/100
Event
Market update
Published
14 Jul 2026 12:12
Source
Investing.com Canada
MarketBeat Direct company coverage

Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH has upgraded Inhibikase Therapeutics (NASDAQ:IKT) to a "strong-buy" rating. This upgrade is part of a generally positive analyst outlook, with Oppenheimer initiating coverage with an outperform rating and a $5.00 price target. The company currently holds an

Tone
Positive 73/100
Event
Analyst action
Published
14 Jul 2026 12:12
Source
MarketBeat
Stock Titan Direct company coverage

Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash

Inhibikase Therapeutics (Nasdaq: IKT) announced the sale of 25 million shares of common stock to RA Capital Management through an at-the-market facility, generating $50 million in gross proceeds. This capital, combined with existing cash, is expected to fund operations through th

Tone
Positive 64/100
Event
Balance sheet
Published
14 Jul 2026 12:12
Source
Stock Titan
TradingView Direct company coverage

Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility

Inhibikase Therapeutics (IKT) sold 25 million shares for $50 million to RA Capital through an at-the-market (ATM) facility. These proceeds, combined with existing cash, are expected to fund operations through the topline Part B readout of the Phase 3 IMPROVE-PAH study. The financ

Tone
Positive 60/100
Event
Balance sheet
Published
14 Jul 2026 12:12
Source
TradingView
MarketBeat Direct company coverage

Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9% - Here's What Happened

Inhibikase Therapeutics (NASDAQ:IKT) shares dropped 3.9% during midday trading on Monday, with the stock closing at $1.96 after reaching a low of $1.95. Trading volume was significantly below average, and the company recently reported earnings that matched Wall Street expectation

Tone
Negative 39/100
Event
Earnings
Published
14 Jul 2026 06:06
Source
MarketBeat
The Manila Times Direct company coverage

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics announced the grant of non-qualified stock options to seven new non-executive employees. These grants, totaling 981,243 shares, were made under the company's 2026 Inducement Equity Plan and approved by the Compensation Committee in accordance with Nasdaq L

Tone
Positive 64/100
Event
Market update
Published
03 Jul 2026 02:40
Source
The Manila Times
Stock Titan Direct company coverage

Inhibikase awards stock options to 7 new hires under inducement plan

Inhibikase Therapeutics (Nasdaq: IKT) granted non-qualified stock options for up to 981,243 shares to seven new non-executive employees under its 2026 Inducement Equity Plan, effective June 30, 2026. These options have an exercise price of $2.03 per share, a ten-year term, and a

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

Director at Inhibikase (NASDAQ: IKT) receives 155K stock options grant

Inhibikase Therapeutics, Inc. director Amit Munshi was granted stock options to acquire 155,000 shares of common stock at an exercise price of $1.91 per share. These options are compensation-related and vest on the earlier of June 26, 2027, or the day before the next annual stock

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 01:39
Source
Stock Titan
Stock Titan Direct company coverage

Inhibikase (IKT) director awarded 155,000 stock options at $1.91 exercise price

Inhibikase Therapeutics, Inc. (IKT) director Arvind Kush was granted 155,000 stock options with an exercise price of $1.91 per share. These options, awarded at no cost, will vest on the earlier of June 26, 2027, or the day before the company's next annual meeting, contingent on h

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 01:39
Source
Stock Titan
Stock Titan Direct company coverage

Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike

Inhibikase Therapeutics director Roberto Bellini was granted 155,000 stock options with an exercise price of $1.91 per share, expiring on June 26, 2036. The options will vest on the earlier of June 26, 2027, or the day before the next annual stockholders' meeting, provided he rem

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Inhibikase (IKT) director Dennis Berman granted options for 155,000 shares

Inhibikase Therapeutics director Dennis N. Berman has been granted stock options for 155,000 shares of common stock, with an exercise price of $1.91 per share and an expiration date of June 26, 2036. The options will vest on the earlier of June 26, 2027, or the day before the nex

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Inhibikase Therapeutics (IKT) director granted 155,000 options at $1.91 strike

Inhibikase Therapeutics (IKT) director Vincent Aurentz was granted 155,000 stock options with an exercise price of $1.91 per share, expiring on June 26, 2036. These options will vest on the earlier of June 26, 2027, or the day before the next annual stockholder meeting, contingen

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike price

Inhibikase Therapeutics, Inc. director David Canner was granted 155,000 stock options with an exercise price of $1.91 per share, expiring on June 26, 2036. The options will vest upon his continued board service, on the earlier of June 26, 2027, or the day before the next annual s

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections

Inhibikase Therapeutics, Inc. stockholders approved all six management proposals at its 2026 annual meeting, including an amendment to its 2020 Equity Incentive Plan to increase shares reserved for issuance by 3,000,000 common shares. They also approved a certificate of amendment

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 09:42
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT

This article focuses on the "Price to book forward" metric for Inhibikase Therapeutics, Inc. (NASDAQ: IKT), indicating financial data for the company. It appears to be a financial data snippet from a larger platform rather than a detailed news analysis. The content is brief and p

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 03:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT

This article provides financial data for Inhibikase Therapeutics, Inc. (NASDAQ: IKT), focusing on its enterprise value to EBITDA forward metric. The information is presented by TradingView, a platform offering market data and financial analysis tools. It highlights key financial

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 13:40
Source
TradingView